Julia Teply-Szymanski

Julia Teply-Szymanski

Auto-generated profile, based on publicly available information

Julia Teply-Szymanski

Institute for Pathology, Philipps-Universität Marburg and University Hospital Marburg (UKGM), Marburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NGNiklas Gremke
Niklas Gremke
FRFiona R. Rodepeter
Fiona R. Rodepeter
JTJulia Teply-Szymanski
Julia Teply-Szymanski
SGSebastian Griewing
Sebastian Griewing
JBJelena Boekhoff
Jelena Boekhoff
EMElisabeth Karin Maria Mack
Elisabeth Karin Maria Mack
Background: Precision oncology treatments are being applied more commonly in breast and gynecological oncology through the implementation of Molecular Tumor Boards (MTBs), but real-world clinical outcome data remain limited. Methods: A retrospective analysis was conducted in patients with breast cancer (BC) and gynecological malignancies referred to our center’s MTB from 2018 to 2023. The analysis covered patient characteristics, next-generation sequencing (NGS) results, MTB recommendations, therapy received, and clinical outcomes. Results: Sixty-three patients (77.8%) had metastatic disease, and forty-four patients (54.3%) had previously undergone three or more lines of systemic treatment. Personalized treatment recommendations were provided to 50 patients (63.3%), while 29 (36.7%) had no actionable target. Ultimately, 23 patients (29.1%) underwent molecular-matched treatment (MMT). Commonly altered genes in patients with pan-gyn tumors (BC and gynecological malignancies) included TP53 (n = 42/81, 51.9%), PIK3CA (n = 18/81, 22.2%), BRCA1/2 (n = 10/81, 12.3%), and ARID1A (n = 9/81, 11.1%). Patients treated with MMT showed significantly prolonged progression-free survival (median PFS 5.5 vs. 3.5 months, p = 0.0014). Of all patients who underwent molecular profiling, 13.6% experienced a major clinical benefit (PFSr ≥ 1.3 and PR/SD ≥ 6 months) through precision oncology. Conclusions: NGS-guided precision oncology demonstrated improved clinical outcomes in a subgroup of patients with gynecological and breast cancers.

12 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TTThomas Samer Tarawneh
Thomas Samer Tarawneh
FRFiona R. Rodepeter
Fiona R. Rodepeter
JTJulia Teply-Szymanski
Julia Teply-Szymanski
PRPetra Ross
Petra Ross
VKVera Koch
Vera Koch
EMElisabeth Karin Maria Mack
Elisabeth Karin Maria Mack
Background: Increasing knowledge of cancer biology and an expanding spectrum of molecularly targeted therapies provide the basis for precision oncology. Despite extensive gene diagnostics, previous reports indicate that less than 10% of patients benefit from this concept. Methods: We retrospectively analyzed all patients referred to our center’s Molecular Tumor Board (MTB) from 2018 to 2021. Molecular testing by next-generation sequencing (NGS) included a 67-gene panel for the detection of short-sequence variants and copy-number alterations, a 53- or 137-gene fusion panel and an ultra-low-coverage whole-genome sequencing for the detection of additional copy-number alterations outside the panel’s target regions. Immunohistochemistry for microsatellite instability and PD-L1 expression complemented NGS. Results: A total of 109 patients were referred to the MTB. In all, 78 patients received therapeutic proposals (70 based on NGS) and 33 were treated accordingly. Evaluable patients treated with MTB-recommended therapy (n = 30) had significantly longer progression-free survival than patients treated with other therapies (n = 17) (4.3 vs. 1.9 months, p = 0.0094). Seven patients treated with off-label regimens experienced major clinical benefits. Conclusion: The combined focused sequencing assays detected targetable alterations in the majority of patients. Patient benefits appeared to lie in the same range as with large-scale sequencing approaches.

23 June 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
JDJan Dreute
Jan Dreute
JSJulia Stengel
Julia Stengel
JBJonas Becher
Jonas Becher
DBDavid van Den Borre
David van Den Borre
MPMaximilian Pfisterer
Maximilian Pfisterer
Lienhard SchmitzLienhard Schmitz
Lienhard Schmitz
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 inhibits lactate dehydrogenase (LDH)A/B and thus effective glycolysis, BMS-986205, in addition to its known inhibitory activity on Indoleamine 2,3-dioxygenase (IDO1), also restricts oxidative phosphorylation (OXPHOS), as revealed here. BMS-986205, which is being tested in multiple Phase III clinical trials, inhibits the ubiquinone reduction site of respiratory complex I and thus compromises mitochondrial ATP production. The energetic catastrophe caused by simultaneous interference with glycolysis and OXPHOS resulted in either cell death or the induction of senescence in tumor cells, with the latter being eliminated by senolytics. The frequent synergy observed with combined inhibitor treatment was comprehensively confirmed through testing on tumor cell lines from the DepMap panel and on human colorectal cancer organoids. These experiments revealed highly synergistic activity of the compounds in a third of the tested tumor cell lines, correlating with alterations in genes with known roles in metabolic regulation and demonstrating the therapeutic potential of metabolic intervention.

8 February 2024 in Laboratory Investigation
Verified
Journal Article
Closed access
MRMarcel Romey
Marcel Romey
FRFiona Rodepeter
Fiona Rodepeter
AHAkira Hattesohl
Akira Hattesohl
KKKristin Kaiser
Kristin Kaiser
JTJulia Teply-Szymanski
Julia Teply-Szymanski
CDCarsten Denkert
Carsten Denkert

4 July 2025 in Histopathology
Verified
Journal Article
Open access
SFSebastian Försch
Sebastian Försch
NHNuwar Harb
Nuwar Harb
ALAnne‐Sophie Litmeyer
Anne‐Sophie Litmeyer
WRWilfried Roth
Wilfried Roth
IBIrina Breus
Irina Breus
MJMoritz Jesinghaus
Moritz Jesinghaus
Aims: Colorectal carcinoma (CRC) is one of the most common cancers worldwide and is associated with significant morbidity and mortality. Histopathology plays a crucial role in the diagnosis, prognostication and treatment planning of CRC. In addition to well‐established morphological parameters such as tumour budding, grade and histopathological subtypes, the interaction between tumour cells and adipose tissue has gained increasing attention.Methods and results: The frequency of direct proximity between cancer cells and adipocytes, termed Stroma Areactive Invasion Front Areas (SARIFA), was assessed in a multicentre cohort of 1,298 patients with pT3/pT4 CRC. The prognostic impact of SARIFA was evaluated, with a particular focus on its relationship with established histopathological parameters. SARIFA was associated with adverse clinicopathological features and served as an indicator of poor prognosis across all survival metrics in the overall cohort (disease‐specific survival [DSS]; P < 0.001). This prognostic value remained significant across all pTNM stages (e.g. DSS in pT3, pN0, pN1/2, pM0 CRC; P < 0.001, respectively) and identified additional adverse prognostic subgroups within tumour budding and grade categories (DSS, P < 0.001, respectively) and within histopathological subtypes. In multivariable analyses, including pTNM stage and the aforementioned histopathological parameters, SARIFA remained a highly significant prognostic factor (DSS P < 0.001, hazard ratio: 1.73).Discussion: Our study confirms the high prognostic relevance of SARIFA across key clinicopathological subgroups of CRC and highlights its value as a meaningful complement to established morphological parameters. Given its ability to provide additional prognostic insights, our findings advocate for its inclusion in pathology reports to improve risk assessment and clinical management.

19 February 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LWLuise von Wichert
Luise von Wichert
ASAlina Stroh
Alina Stroh
MWMarie Witt
Marie Witt
MWMichael Wanzel
Michael Wanzel
MMMarco Mernberger
Marco Mernberger
NGNiklas Gremke
Niklas Gremke
Breast cancer (BC) is the most prevalent malignancy in women, with hormone receptor-positive, HER2-negative (HR + /HER2 − ) tumors representing ~70% of cases. While CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have transformed treatment for metastatic HR + /HER2 − BC, acquired resistance remains a major obstacle. Using HR + /HER2 − BC models with acquired resistance to the CDK4/6 inhibitors Palbociclib or Ribociclib, we uncovered a metabolic vulnerability in highly resistant clones, mediated by mTORC1 hyperactivation and autophagy suppression. Gene expression profiling revealed enrichment of glycolysis and mTORC1 pathways in CDK4/6i-resistant cells, which manifested as heightened sensitivity to the metabolic inhibitors Metformin and Dichloroacetate (DCA). Mechanistically, mTORC1 overactivation impaired autophagy via ULK1-Ser757 phosphorylation, as confirmed by LC3 flux assays, leaving resistant cells unable to adapt to energy stress. Treatment with metabolic drugs triggered AMPK activation, ACC inhibition, and PARP cleavage, culminating in apoptosis. Clinically, immunohistochemical analysis of a BC cohort revealed a significant correlation between mTORC1 activity (p4E-BP1 T37/46 ) and autophagy suppression (p62 accumulation), supporting the translational relevance of this axis. Our findings propose mTORC1-mediated autophagy defects as a biomarker for metabolic vulnerability in CDK4/6i-resistant BC, offering a rationale for targeting these tumors with metabolic therapies to overcome resistance.